These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. [Current data on neurologic sequelae caused by neuroleptics]. Krebs MO Encephale; 1995 Jun; 21 Spec No 3():49-52. PubMed ID: 7628342 [TBL] [Abstract][Full Text] [Related]
25. [Neurologic complications following medical treatment of epileptic patients]. Boldyrev AI; Fleĭs EP; Vaĭntrub MIa Zh Nevropatol Psikhiatr Im S S Korsakova; 1979; 79(6):738-41. PubMed ID: 224628 [TBL] [Abstract][Full Text] [Related]
26. Toxicity to the nervous system of diphenylhydantoin: a review. Ziegler DK Int J Neurol; 1978; 11(4):383-400. PubMed ID: 94596 [No Abstract] [Full Text] [Related]
27. Measuring movement disorders in antipsychotic drug trials: the need to define a new standard. Loonen AJ; van Praag HM J Clin Psychopharmacol; 2007 Oct; 27(5):423-30. PubMed ID: 17873670 [No Abstract] [Full Text] [Related]
28. Pathophysiology of antipsychotic drug-induced movement disorders. Casey DE J Clin Psychiatry; 2004; 65 Suppl 9():25-8. PubMed ID: 15189109 [TBL] [Abstract][Full Text] [Related]
29. [Lesions of the nervous system in drug-induced illnesses]. Korochkin IM; Samoĭlova LN; Tarasova LA Zh Nevropatol Psikhiatr Im S S Korsakova; 1984; 84(8):1172-6. PubMed ID: 6093412 [TBL] [Abstract][Full Text] [Related]
30. [Toxic neurologic manifestations during angina pectoris treatment (perhexiline maleate and amiotadone hydrochloride)]. Bady B; Bourrat C; Trillet M; Girard PF; Carrier H Int J Neurol; 1978; 11(4):371-82. PubMed ID: 232499 [No Abstract] [Full Text] [Related]
33. Involuntary movement disorders--each has a meaning all its own. Kramer J; Klawans HL Geriatrics; 1979 Sep; 34(9):63-71. PubMed ID: 38189 [TBL] [Abstract][Full Text] [Related]
34. Prolonged sensory/motor deficits following inadvertent spinal anesthesia. Covino BG; Marx GF; Finster M; Zsigmond EK Anesth Analg; 1980 Jun; 59(6):399-400. PubMed ID: 7189974 [No Abstract] [Full Text] [Related]
35. [Somatic disorders during long-term drug treatment of schizophrenic patients]. vom Brocke I Internist (Berl); 1974 May; 15(5):268-70. PubMed ID: 4213663 [No Abstract] [Full Text] [Related]
36. Current concepts of abnormal motor disorder: an experimental model of attentional deficit disorder. Wray SR; Melville GN; Grell GA; Edge PC West Indian Med J; 1981 Sep; 30(3):107-18. PubMed ID: 6117153 [No Abstract] [Full Text] [Related]
37. [Neurologic disorders caused by adverse effects of drugs--with special reference to iatrogenic nervous system diseases of the current interest]. Kuzuhara S Nihon Naika Gakkai Zasshi; 1998 Sep; 87(9):1885-91. PubMed ID: 9816868 [No Abstract] [Full Text] [Related]
38. Hypophosphataemia and reversible neurological dysfunction in a patient subjected to combined renal and pancreatic transplantation. Tydén G; Fehrman I; Sidén A; Persson A Nephrol Dial Transplant; 1988; 3(6):823-5. PubMed ID: 3147428 [No Abstract] [Full Text] [Related]
39. [Neuroleptics in children]. Daléry J; Beaufrère B; Maillet J; de Villard R Pediatrie; 1980; 35(1):89-94. PubMed ID: 6102756 [No Abstract] [Full Text] [Related]
40. Movement disorders with neuroleptic drug treatment. Tarsy D Psychiatr Clin North Am; 1984 Sep; 7(3):453-71. PubMed ID: 6148742 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]